Back to Headlines
Society
Mar 31, 2026

UK Calls for Tighter Regulation on Private Cannabis Clinics After Fatal Prescription

AI Summary
The brother of a man who died after being prescribed medicinal cannabis is calling for tighter regulation on private UK cannabis clinics, citing concerns over the lack of oversight and evidence supporting its use for mental health conditions.

The tragic case of Oliver Robinson, a 34-year-old who took his own life in November 2023, has sparked a campaign for stricter controls on private cannabis clinics in the UK. An inquest concluded that Robinson's prescription for medicinal cannabis, issued by Curaleaf Clinic, probably contributed to his death and acted as an obstacle to him receiving proper psychiatric and addiction care.

Robinson had been struggling with depression and addiction, and had been treated at the Priory, a private mental health facility. He was initially prescribed medicinal cannabis in May 2022, which initially provided relief but ultimately worsened his condition. The coroner's report highlighted several failings in his care, including the use of an out-of-date GP summary care record and incomplete information in prescribing decisions.

Alexander Robinson, Oliver's brother, is now advocating for tighter regulation of private cannabis clinics, including a ban on prescribing to patients with serious mental illness and greater oversight of the rapidly expanding industry. He believes that the current safeguards are not strong enough to protect vulnerable psychiatric patients.

The UK government reported about 5,000 NHS prescriptions for licensed cannabis-based medicinal products in 2023, while freedom of information data showed that 659,293 unlicensed cannabis products were privately prescribed in 2024, more than double the number issued in 2023. Critics argue that there is limited evidence that cannabis is an effective treatment for depression and other common mental health conditions.

Dr. Pavan Chahl, an expert psychiatrist, told Oliver's inquest that medicinal cannabis should not have been prescribed to someone with a history of severe psychiatric disorder, citing a lack of evidence for efficacy in depression and the risk of worsening symptoms. In response to the campaign, Curaleaf Clinic stated that it would engage constructively with any review or consultation aimed at strengthening patient safety across the sector.